Kimberly Murphy
Director/Board Member bei ORAGENICS, INC.
Vermögen: 36 000 $ am 31.03.2024
Profil
Kimberly M.
Murphy is currently the Director at Oragenics, Inc. and an Independent Director at Blue Water Acquisition Corp.
II.
Previously, she served as the Chairman at Clarus Therapeutics, Inc. and Clarus Therapeutics Holdings, Inc. She also worked as the Director-HPV & Gardasil Franchise at Merck & Co., Inc. and as a Director at the Biotechnology Innovation Organization.
Additionally, she held the position of Independent Non-Executive Director at Blue Water Biotech, Inc. and served as an Independent Director at Blue Water Acquisition Corp.
In the past, she was the Vice President at Novartis AG and GSK Plc.
Ms. Murphy completed her undergraduate degree at Old Dominion University and holds an MBA from St. Joseph's University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ORAGENICS, INC.
0,56% | 15.03.2024 | 25 000 ( 0,56% ) | 36 000 $ | 31.03.2024 |
Aktive Positionen von Kimberly Murphy
| Unternehmen | Position | Beginn |
|---|---|---|
| ORAGENICS, INC. | Director/Board Member | 01.05.2020 |
Blue Water Acquisition Corp. II
 Blue Water Acquisition Corp. II Financial ConglomeratesFinance Blue Water Acquisition Corp. II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Joseph Hernandez and is headquartered in Greenwich, CT. | Director/Board Member | - |
Ehemalige bekannte Positionen von Kimberly Murphy
| Unternehmen | Position | Ende |
|---|---|---|
Blue Water Biotech, Inc.
 Blue Water Biotech, Inc. Pharmaceuticals: MajorHealth Technology Blue Water Biotech, Inc. is a biotechnology company, which engages in the research and development of transformational vaccines to prevent infectious diseases worldwide. Its platform includes the BWV Norovirus (NoV) S&P Nanoparticle Versatile Vaccine. Bioengineering the shell (S) and protruding (P) domains of the norovirus capsid protein, polyvalent nanoparticles and polymers/oligomers provide a versatile vaccine platform with wide applications. The company was founded by Joseph Hernandez on October 26, 2018 and is headquartered in Cincinnati, OH. | Director/Board Member | 13.01.2023 |
| CLARUS THERAPEUTICS HOLDINGS, INC. | Chairman | 31.10.2022 |
| GSK PLC | Corporate Officer/Principal | 01.01.2019 |
| NOVARTIS AG | Corporate Officer/Principal | 01.05.2015 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01.01.2005 |
Ausbildung von Kimberly Murphy
| Old Dominion University | Undergraduate Degree |
| St. Joseph's University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ORAGENICS, INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| GSK PLC | Health Technology |
| CLARUS THERAPEUTICS HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Clarus Therapeutics, Inc.
 Clarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Clarus Therapeutics, Inc. operated as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy. It offered JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company was founded by Robert E. Dudley in February 2004 and was headquartered in Northbrook, IL. | Health Technology |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Blue Water Biotech, Inc.
Blue Water Biotech, Inc. Pharmaceuticals: MajorHealth Technology Blue Water Biotech, Inc. is a biotechnology company, which engages in the research and development of transformational vaccines to prevent infectious diseases worldwide. Its platform includes the BWV Norovirus (NoV) S&P Nanoparticle Versatile Vaccine. Bioengineering the shell (S) and protruding (P) domains of the norovirus capsid protein, polyvalent nanoparticles and polymers/oligomers provide a versatile vaccine platform with wide applications. The company was founded by Joseph Hernandez on October 26, 2018 and is headquartered in Cincinnati, OH. | Health Technology |
Blue Water Acquisition Corp.
 Blue Water Acquisition Corp. Financial ConglomeratesFinance Blue Water Acquisition Corp. operates as a blank check company. It is incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded by Joseph Hernandez on May 22, 2020 and is headquartered in Greenwich, CT. | Finance |
Blue Water Acquisition Corp. II
Blue Water Acquisition Corp. II Financial ConglomeratesFinance Blue Water Acquisition Corp. II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Joseph Hernandez and is headquartered in Greenwich, CT. | Finance |
